Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials

RMD Open

Volumn 3, Issue 2, 2017, Pages

  Strand, Vibeke ^a   Michalska, Margaret ^b   Birchwood, Christine ^b   Pei, Jinglan ^b   Tuckwell, Katie ^b   Finch, Rebecca ^c   Gabay, Cem ^d   Kavanaugh, Arthur ^e   Jones, Graeme ^f  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GENENTECH INC   (United States)

^c PDBB Biostatistics   (United Kingdom)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF TASMANIA   (Australia)

Author keywords

monotherapy; patient reported outcomes; rheumatoid arthritis; tocilizumab

Indexed keywords

ADALIMUMAB; METHOTREXATE; TOCILIZUMAB;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; FEMALE; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE; FUNCTIONAL STATUS ASSESSMENT; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL COMPONENT SUMMARY; MENTAL HEALTH; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; PAIN; PATIENT ASSESSMENT; PATIENT GLOBAL ASSESSMENT; PATIENT-REPORTED OUTCOME; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PHYSICAL CAPACITY; PHYSICAL COMPONENT SUMMARY; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SHORT FORM 36;

EID: 85034612687     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2017-000496     Document Type: Article

References (24)

1. Austad C, Kvien TK, Olsen IC, et al. Sleep disturbance in patients with rheumatoid arthritis is related to fatigue, disease activity, and other patient-reported outcomes. Scand J Rheumatol 2017;46:95-103.
2. Strand V, Khanna D. The impact of rheumatoid arthritis and treatment on patients' lives. Clin Exp Rheumatol 2010;28:32-40.
3. van Vilsteren M, Boot CR, Knol DL, et al. Productivity at work and quality of life in patients with rheumatoid arthritis. BMC Musculoskelet Disord 2015;16:107.
4. Wan SW, He HG, Mak A, et al. Health-related quality of life and its predictors among patients with rheumatoid arthritis. Appl Nurs Res 2016;30:176-83.
5. Deshpande PR, Rajan S, Sudeepthi BL, et al. Patient-reported outcomes: A new era in clinical research. Perspect Clin Res 2011;2:137-44.
6. Her M, Kavanaugh A. Patient-reported outcomes in rheumatoid arthritis. Curr Opin Rheumatol 2012;24:327-34.
7. Kalyoncu U, Dougados M, Daurès J P, et al. Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2009;68:183-90.
8. Kirwan JR, Hewlett SE, Heiberg T, et al. Incorporating the patient perspective into outcome assessment in rheumatoid arthritis-progress at OMERACT 7. J Rheumatol 2005;32:2250-6.
9. Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs 2010;70:121-5.
10. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res 2016:68:1-25.
11. Catay E, Bravo M, Rosa J, Soriano ER, et al. Prevalence of biologics monotherapy in a cohort of patients with Rheumatoid Arthritis in daily clinical practice. BMC Musculoskelet Disord 2016;17:110.
12. Pappas DA, Reed GW, Saunders K, et al. Characteristics Associated with Biologic Monotherapy Use in Biologic-Naive Patients with Rheumatoid Arthritis in a US Registry Population. Rheumatol Ther 2015;2:85-96.
13. Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013;72:43-50.
14. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29.
15. Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381:1541-50.
16. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96.
17. Strand V, Burmester GR, Ogale S, et al. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. Rheumatology 2012;51:1860-9.
18. Strand V, Boers M, Idzerda L, et al. It's good to feel better but it's better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10. J Rheumatol 2011;38:1720-7.
19. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes 2003;1:79.
20. Krishnan E, Tugwell P, Fries JF. Percentile benchmarks in patients with rheumatoid arthritis: Health Assessment Questionnaire as a quality indicator (QI). Arthritis Res Ther 2004;6:R505-13.
21. Strand V, Crawford B, Singh J, et al. Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases. Ann Rheum Dis 2009;68:1800-4.
22. Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013;72:43-50.
23. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
24. Strand V, Rentz AM, Cifaldi MA, et al. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study. J Rheumatol 2012;39:63-72.